Benkhadra, M.; Fituri, N.; Aboukhalaf, S.; Ghasoub, R.; Mattar, M.; Alfarsi, K.; Alshemmari, S.; Yassin, M.A.
The Safety of Novel Therapies in Chronic Lymphocytic Leukemia in the Era of Intermittent Fasting: A Pharmacology-Based Review. Cancers 2024, 16, 2079.
https://doi.org/10.3390/cancers16112079
AMA Style
Benkhadra M, Fituri N, Aboukhalaf S, Ghasoub R, Mattar M, Alfarsi K, Alshemmari S, Yassin MA.
The Safety of Novel Therapies in Chronic Lymphocytic Leukemia in the Era of Intermittent Fasting: A Pharmacology-Based Review. Cancers. 2024; 16(11):2079.
https://doi.org/10.3390/cancers16112079
Chicago/Turabian Style
Benkhadra, Maria, Nuha Fituri, Soha Aboukhalaf, Rola Ghasoub, Mervat Mattar, Khalil Alfarsi, Salem Alshemmari, and Mohamed A. Yassin.
2024. "The Safety of Novel Therapies in Chronic Lymphocytic Leukemia in the Era of Intermittent Fasting: A Pharmacology-Based Review" Cancers 16, no. 11: 2079.
https://doi.org/10.3390/cancers16112079
APA Style
Benkhadra, M., Fituri, N., Aboukhalaf, S., Ghasoub, R., Mattar, M., Alfarsi, K., Alshemmari, S., & Yassin, M. A.
(2024). The Safety of Novel Therapies in Chronic Lymphocytic Leukemia in the Era of Intermittent Fasting: A Pharmacology-Based Review. Cancers, 16(11), 2079.
https://doi.org/10.3390/cancers16112079
